Asahi Kasei Introduces MOTIV Buffer Management

MOTIV is designed to keep pharmaceutical production moving efficiently and precisely.

By: Kristin Brooks

Managing Editor, Contract Pharma

Asahi Kasei Bioprocess, subsidiary of Japanese technology company Asahi Kasei showcased it MOTIV Buffer Management Technology at ACHEMA 2022 in Frankfurt in August. Using built-in automation software, MOTIV is designed to keep pharmaceutical production moving efficiently and precisely, so that medicine can be produced in larger quantities and be made more available globally.
 
Buffers are used for the vast majority of processes in pharmaceutical development, which has traditionally required storage in extremely large tank farms to be utilized as necessary. MOTIV can blend buffers from concentrates in small, single-use bags and is controlled with sensors to maintain and assure precision, according to the company. It is also able to blend buffers to exact specifications as needed during a downstream development process and can handle a wide variety of buffer formulations. MOTIV is automated by the integrated OCELOT System Control software, a technology that integrates and/or interfaces with plant-wide control systems in a universally compatible format, allowing for data collection and analysis. OCELOT makes the whole process repeatable and also helps to reduce waste created in the development process.
 
“We have been working to ‘standardize’ system designs as much as we can, to make them more readily available with shorter lead times; but are also very capable at building custom systems to meet the specific needs of customers,” said Chris Rombach, Vice President of Sales and Marketing at Asahi Kasei Bioprocess America. “One of our strengths is not only having an innovative product, but also an extensive family of MOTIV systems to choose from. Buffer is the lifeblood of pharma manufacturing and with the R&D opportunities of being a part of the Asahi Kasei Group we have been able to develop MOTIV to be the most reliable and efficient IBF technology in the market today. Not to mention, Operation Warp Speed helped push capacity to expand globally and billions of dollars are being invested by manufacturers to ramp up production as quickly as possible. This drives a new sense of value for systems like our MOTIV family that can streamline processes.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters